Johnson & Johnson (NYSE:JNJ) Shares Sold by Thomasville National Bank

Thomasville National Bank cut its holdings in Johnson & Johnson (NYSE:JNJ) by 5.4% during the fourth quarter, HoldingsChannel reports. The fund owned 20,234 shares of the company’s stock after selling 1,162 shares during the period. Thomasville National Bank’s holdings in Johnson & Johnson were worth $2,926,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in the business. Parkside Advisors LLC lifted its holdings in Johnson & Johnson by 29.0% in the fourth quarter. Parkside Advisors LLC now owns 5,124 shares of the company’s stock valued at $741,000 after acquiring an additional 1,153 shares during the last quarter. Kieckhefer Group LLC acquired a new position in Johnson & Johnson in the fourth quarter valued at approximately $275,000. Trust Co. of Toledo NA OH lifted its holdings in Johnson & Johnson by 8.5% in the fourth quarter. Trust Co. of Toledo NA OH now owns 44,208 shares of the company’s stock valued at $6,393,000 after acquiring an additional 3,471 shares during the last quarter. Fiduciary Alliance LLC lifted its holdings in Johnson & Johnson by 7.1% in the fourth quarter. Fiduciary Alliance LLC now owns 78,738 shares of the company’s stock valued at $11,387,000 after acquiring an additional 5,245 shares during the last quarter. Finally, Crescent Sterling Ltd. lifted its stake in Johnson & Johnson by 0.3% during the fourth quarter. Crescent Sterling Ltd. now owns 23,239 shares of the company’s stock worth $3,361,000 after purchasing an additional 72 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Johnson & Johnson news, Director Mark A. Weinberger bought 1,000 shares of the firm’s stock in a transaction dated Thursday, December 12th. The stock was acquired at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the purchase, the director now owns 1,000 shares of the company’s stock, valued at approximately $147,220. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.16% of the company’s stock.

Analyst Ratings Changes

A number of research firms have commented on JNJ. Bank of America restated a “neutral” rating and set a $166.00 price target on shares of Johnson & Johnson in a research note on Tuesday, December 10th. Citigroup decreased their price target on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a research note on Wednesday, December 11th. Wells Fargo & Company upped their price target on Johnson & Johnson from $163.00 to $166.00 and gave the stock an “equal weight” rating in a research note on Wednesday, October 16th. Guggenheim upped their price target on Johnson & Johnson from $156.00 to $162.00 and gave the stock a “neutral” rating in a research note on Wednesday, November 6th. Finally, StockNews.com cut Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, January 7th. Seven investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, Johnson & Johnson presently has an average rating of “Moderate Buy” and an average price target of $174.71.

Johnson & Johnson Stock Up 0.4 %

NYSE:JNJ traded up $0.60 during trading hours on Monday, hitting $142.66. The company’s stock had a trading volume of 3,038,824 shares, compared to its average volume of 7,282,141. The stock has a market capitalization of $343.47 billion, a P/E ratio of 20.65, a price-to-earnings-growth ratio of 2.52 and a beta of 0.51. The stock has a fifty day moving average of $149.67 and a 200-day moving average of $156.11. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $168.85.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, beating the consensus estimate of $2.21 by $0.21. The firm had revenue of $22.47 billion for the quarter, compared to analyst estimates of $22.17 billion. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. Johnson & Johnson’s revenue for the quarter was up 5.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.66 earnings per share. On average, equities analysts forecast that Johnson & Johnson will post 9.94 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be issued a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a dividend yield of 3.48%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s payout ratio is 71.78%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.